We provide you with 20 years of free, institutional-grade data for CRBU stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of CRBU. Explore the full financial landscape of CRBU stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2024-03-11 | 1619856 | CRBU | 10-K | Url |
| 2023-11-07 | 1619856 | CRBU | 10-Q | Url |
| 2023-08-08 | 1619856 | CRBU | 10-Q | Url |
| 2023-05-09 | 1619856 | CRBU | 10-Q | Url |
| 2023-03-09 | 1619856 | CRBU | 10-K | Url |
| 2022-11-08 | 1619856 | CRBU | 10-Q | Url |
| 2022-08-09 | 1619856 | CRBU | 10-Q | Url |
| 2022-05-09 | 1619856 | CRBU | 10-Q | Url |
| 2022-03-21 | 1619856 | CRBU | 10-K | Url |
| 2021-11-09 | 1619856 | CRBU | 10-Q | Url |
| 2021-09-02 | 1619856 | CRBU | 10-Q | Url |
| 2021-07-01 | 1619856 | CRBU | S-1 | Url |
Caribou Biosciences Inc(NASDAQ:CRBU) 
Caribou Biosciences is a biotechnology company that develops CRISPR technologies and allogenic cell therapies for oncology.
Website: https://www.cariboubio.com/
Founded: 2011
CEO / Co-Founder: Rachel Haurwitz
Sector:
Industry:
Share this website to your friends
The information provided in this report about CRBU stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.